Frog - What you say is true for any product developement decisions...but it cannot and does not take away from the fact that one of the nation's most prestigious cancer research chose DNAPrint Genomics...
And I don't think they simply put names up on the wall and threw darts. They have weighed the risks against the rewards and I'm sure they found the weighted benefits of the rewards far exceed the minimum risk of taking away resources from other projects... They do these types of decisions every day.
The pay-back in time and cost savings for discovering markers and future drug development could prove to be immense for the Moffitt center, and I am sure their top scientists calculated all this out before! And as a side-bet, I'd say Moffitt's scientists are in fact excited to be working with DNAP's revolutionary discovery platform...
And what you stated about "DNAP stepping up to the plate" is very appropriate. Even Dr. Frudakis indicated that "...this is by far the most exciting research and product development opportunity yet for our young company." So yes, definitely time to step up... However...
Wth the previous successful validations of Ovanome, Statnome, Retinome, DNA Witness, and AncestryByDNA, DNAP's success with the upcoming clinical trials is more than highly likely...
The KEY is that the ADMIXMAP DISCOVERY PLATFORM has been validated... With the risk of oversimplifying, the rest is just putting in the time and the data...
Thanks for your views, tho I tend to agree with Chig and see these issues as very moot....or simply grasping at straws...
God Bless and take care,
Robert
News 
Market Data 
Discover 
